Parathyroid cancer.

Sandy H Fang, Geeta Lal

Research output: Contribution to journalArticle

Abstract

To review the current knowledge pertaining to the etiology, molecular pathogenesis, and management of parathyroid carcinoma, a rare presentation of primary hyperparathyroidism. The existing MEDLINE English-language literature was reviewed using the search terms "parathyroid" and "carcinoma" or "cancer." Parathyroid cancer is a rare endocrine tumor accounting for a small proportion of cases of primary hyperparathyroidism. Recent database studies indicate increasing incidence rates. Its etiology is unknown, although numerous molecular alterations have been described, and the tumors also occur in association with germline mutations in the CDC73 gene. Most affected patients present with severe hypercalcemia; however, the diagnosis can be challenging. Complete surgical resection remains the mainstay of treatment and provides the best chance of cure, although data from small series suggest that external beam radiation may also reduce the high recurrence rates. No effective chemotherapy regimens are currently available. A significant number of patients develop recurrent disease and need additional procedures; however, long-term survival is possible with palliative surgery. Medical management of chronic and debilitating hypercalcemia with calcimimetics is often necessary and is an important adjunct in patients with recurrent and metastatic disease. Further elucidation of the molecular pathogenesis of parathyroid carcinomas will enhance our understanding of etiology and behavior of this uncommon entity. Future research must be directed at identifying more effective therapies for this condition.

Original languageEnglish (US)
Pages (from-to)36-43
Number of pages8
JournalEndocrine Practice
Volume17 Suppl 1
DOIs
StatePublished - Mar 2011
Externally publishedYes

Fingerprint

Parathyroid Neoplasms
Primary Hyperparathyroidism
Hypercalcemia
Neoplasms
Germ-Line Mutation
Palliative Care
MEDLINE
Language
Databases
Radiation
Recurrence
Drug Therapy
Survival
Incidence
Therapeutics
Genes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Parathyroid cancer. / Fang, Sandy H; Lal, Geeta.

In: Endocrine Practice, Vol. 17 Suppl 1, 03.2011, p. 36-43.

Research output: Contribution to journalArticle

Fang, Sandy H ; Lal, Geeta. / Parathyroid cancer. In: Endocrine Practice. 2011 ; Vol. 17 Suppl 1. pp. 36-43.
@article{6fc7be08154b41b38710904df02914af,
title = "Parathyroid cancer.",
abstract = "To review the current knowledge pertaining to the etiology, molecular pathogenesis, and management of parathyroid carcinoma, a rare presentation of primary hyperparathyroidism. The existing MEDLINE English-language literature was reviewed using the search terms {"}parathyroid{"} and {"}carcinoma{"} or {"}cancer.{"} Parathyroid cancer is a rare endocrine tumor accounting for a small proportion of cases of primary hyperparathyroidism. Recent database studies indicate increasing incidence rates. Its etiology is unknown, although numerous molecular alterations have been described, and the tumors also occur in association with germline mutations in the CDC73 gene. Most affected patients present with severe hypercalcemia; however, the diagnosis can be challenging. Complete surgical resection remains the mainstay of treatment and provides the best chance of cure, although data from small series suggest that external beam radiation may also reduce the high recurrence rates. No effective chemotherapy regimens are currently available. A significant number of patients develop recurrent disease and need additional procedures; however, long-term survival is possible with palliative surgery. Medical management of chronic and debilitating hypercalcemia with calcimimetics is often necessary and is an important adjunct in patients with recurrent and metastatic disease. Further elucidation of the molecular pathogenesis of parathyroid carcinomas will enhance our understanding of etiology and behavior of this uncommon entity. Future research must be directed at identifying more effective therapies for this condition.",
author = "Fang, {Sandy H} and Geeta Lal",
year = "2011",
month = "3",
doi = "10.4158/EP10310.RA",
language = "English (US)",
volume = "17 Suppl 1",
pages = "36--43",
journal = "Endocrine Practice",
issn = "1530-891X",
publisher = "American Association of Clinical Endocrinology",

}

TY - JOUR

T1 - Parathyroid cancer.

AU - Fang, Sandy H

AU - Lal, Geeta

PY - 2011/3

Y1 - 2011/3

N2 - To review the current knowledge pertaining to the etiology, molecular pathogenesis, and management of parathyroid carcinoma, a rare presentation of primary hyperparathyroidism. The existing MEDLINE English-language literature was reviewed using the search terms "parathyroid" and "carcinoma" or "cancer." Parathyroid cancer is a rare endocrine tumor accounting for a small proportion of cases of primary hyperparathyroidism. Recent database studies indicate increasing incidence rates. Its etiology is unknown, although numerous molecular alterations have been described, and the tumors also occur in association with germline mutations in the CDC73 gene. Most affected patients present with severe hypercalcemia; however, the diagnosis can be challenging. Complete surgical resection remains the mainstay of treatment and provides the best chance of cure, although data from small series suggest that external beam radiation may also reduce the high recurrence rates. No effective chemotherapy regimens are currently available. A significant number of patients develop recurrent disease and need additional procedures; however, long-term survival is possible with palliative surgery. Medical management of chronic and debilitating hypercalcemia with calcimimetics is often necessary and is an important adjunct in patients with recurrent and metastatic disease. Further elucidation of the molecular pathogenesis of parathyroid carcinomas will enhance our understanding of etiology and behavior of this uncommon entity. Future research must be directed at identifying more effective therapies for this condition.

AB - To review the current knowledge pertaining to the etiology, molecular pathogenesis, and management of parathyroid carcinoma, a rare presentation of primary hyperparathyroidism. The existing MEDLINE English-language literature was reviewed using the search terms "parathyroid" and "carcinoma" or "cancer." Parathyroid cancer is a rare endocrine tumor accounting for a small proportion of cases of primary hyperparathyroidism. Recent database studies indicate increasing incidence rates. Its etiology is unknown, although numerous molecular alterations have been described, and the tumors also occur in association with germline mutations in the CDC73 gene. Most affected patients present with severe hypercalcemia; however, the diagnosis can be challenging. Complete surgical resection remains the mainstay of treatment and provides the best chance of cure, although data from small series suggest that external beam radiation may also reduce the high recurrence rates. No effective chemotherapy regimens are currently available. A significant number of patients develop recurrent disease and need additional procedures; however, long-term survival is possible with palliative surgery. Medical management of chronic and debilitating hypercalcemia with calcimimetics is often necessary and is an important adjunct in patients with recurrent and metastatic disease. Further elucidation of the molecular pathogenesis of parathyroid carcinomas will enhance our understanding of etiology and behavior of this uncommon entity. Future research must be directed at identifying more effective therapies for this condition.

UR - http://www.scopus.com/inward/record.url?scp=79959491615&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959491615&partnerID=8YFLogxK

U2 - 10.4158/EP10310.RA

DO - 10.4158/EP10310.RA

M3 - Article

C2 - 21454239

AN - SCOPUS:79959491615

VL - 17 Suppl 1

SP - 36

EP - 43

JO - Endocrine Practice

JF - Endocrine Practice

SN - 1530-891X

ER -